Evidence map›Paper›PMID 32872120›Full record

ArticleJournal of personalized medicine2020

Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted,

László Urbán, Róbert Dóczi, Barbara Vodicska, Dóra Kormos, László Tóth, István Takács, Edit Várkondi, Dóra Tihanyi, Dóra Lakatos, Anna Dirner and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

László UrbánDepartment of Pulmonology, Mátraháza University and Teaching Hospital, 3233 Mátraháza, Hungary.
Róbert DócziOncompass Medicine Hungary Ltd., 1024 Budapest, Hungary.
Barbara VodicskaOncompass Medicine Hungary Ltd., 1024 Budapest, Hungary.
Dóra KormosDepartment of Internal Medicine and Lymphomatherapy V., BAZ County Central and Teaching Hospital, 3526 Miskolc, Hungary.
László TóthDepartment of Pulmonology, Mátraháza University and Teaching Hospital, 3233 Mátraháza, Hungary.
István TakácsDepartment of Internal Medicine and Lymphomatherapy V., BAZ County Central and Teaching Hospital, 3526 Miskolc, Hungary.
Edit VárkondiOncompass Medicine Hungary Ltd., 1024 Budapest, Hungary.
Dóra TihanyiOncompass Medicine Hungary Ltd., 1024 Budapest, Hungary.
Dóra LakatosOncompass Medicine Hungary Ltd., 1024 Budapest, Hungary.
Anna DirnerOncompass Medicine Hungary Ltd., 1024 Budapest, Hungary.
István Vályi-NagyNational Hematology and Infectology Institute, Centrum Hospital of Southern Pest, 1097 Budapest, Hungary.
István PetákOncompass Medicine Hungary Ltd., 1024 Budapest, Hungary.
University of Miskolc · HUUniversity of Illinois Chicago · US

Funding

Nemzeti Kutatási, Fejlesztési és Innovaciós Alap 2019-1.1.1-PIACI-KFI-2019-00367Nemzeti Kutatási, Fejlesztési és Innovaciós Alap NVKP_16-1-2016-0005
6 · The paper itself

Abstract

backgroundThe anaplastic lymphoma kinase (

methodsWe report the case of an

resultsThe tumor showed progression on crizotinib, but long tumor control was achieved following the incremental administration of next-generation ALK inhibitors, despite lack of evident resistance mechanisms.

conclusion

Indexed as

ALK rearrangementNSCLCpersonalized treatmentTKITP53 mutation

Identifiers

PMID32872120
PMCPMC7563786
OpenAlexW3080561234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.